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Abstract: Traditional methods for discovery and development of new drugs can be very
time-consuming and expensive processes because they include several stages, such as compound
identification, pre-clinical and clinical trials before the drug is approved by the U.S. Food and
Drug Administration (FDA). Therefore, drug repurposing, namely using currently FDA-approved
drugs as therapeutics for other diseases than what they are originally prescribed for, is emerging
to be a faster and more cost-effective alternative to current drug discovery methods. In this paper,
we have described a three-step in silico protocol for analyzing transcriptomics data using online
databases and bioinformatics tools for identifying potentially repurposable drugs. The efficacy
of this protocol was evaluated by comparing its predictions with the findings of two case studies
of recently reported repurposed drugs: HIV treating drug zidovudine for the treatment of dry
age-related macular degeneration and the antidepressant imipramine for small-cell lung carcinoma.
The proposed protocol successfully identified the published findings, thus demonstrating the efficacy
of this method. In addition, it also yielded several novel predictions that have not yet been published,
including the finding that imipramine could potentially treat Severe Acute Respiratory Syndrome
(SARS), a disease that currently does not have any treatment or vaccine. Since this in silico protocol is
simple to use and does not require advanced computer skills, we believe any motivated participant
with access to these databases and tools would be able to apply it to large datasets to identify other
potentially repurposable drugs in the future.
Keywords: drug repurposing; translational bioinformatics; transcriptomics; transcriptome analysis;
drug discovery; computational protocol; gene expression
1. Introduction
De novo methods for drug discovery can be incredibly expensive and time consuming. A target
molecule, such as a gene that is causally linked to a disease, is first identified to initiate the drug
discovery process. Scientists then systematically screen for small molecules that modulate the target
protein-product and carry out a series of optimization steps to improve the efficacy of the lead drug.
Next, periods of animal studies are followed by clinical trials before a drug can be approved for
the market by the USA Food and Drug Administration (FDA) (or its counterpart in other countries).
Usually, this procedure costs four to 12 billion dollars and takes an average of 12 to 17 years to
complete [1]. Unfortunately, in some cases, this may not result in any successful drug that is safe for
human use. For example, if a promising drug starts to reveal severe side effects during clinical trials,
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the drug is discarded, and the resources invested would thus be wasted. Due to these limitations, only
50 new drugs could be approved by the U.S. FDA during a period of ten years from 1999 to 2008 [2].
In order to make the current drug discovery practices more efficient or productive, a new
approach based on repurposing the existing FDA-approved drugs for new diseases has recently
gained traction [1]. Drug repurposing, which is typically based on systems biology and data
analytics, could drastically reduce both the cost and time associated with finding suitable drugs
for diseases. There are several drugs that were successfully repurposed to treat new diseases [3],
of which some well-known examples include: anti-angina drug sildenafil citrate repurposed to treat
erectile dysfunction [4], the diabetes medicine metformin that has potential use for cancer treatment [5],
HIV drug nucleoside reverse transcriptase inhibitors that could treat “dry” age-related macular
degeneration [6] and imipramine, a tricyclic antidepressant, with potential to treat small-cell lung
carcinoma [7].
A common method of identifying repurposed drugs is based on the following principle.
Human cells maintain homeostasis through the regulated expression of their transcriptome.
A perturbation of cellular gene expression often leads to the manifestation of a disease state; hence,
each disease normally reveals a signature gene expression profile [8]. When a suitable drug is
administered to treat a disease, it tends to correct the aberration by bringing the gene expression
pattern back to its normal state. Thus, a negative correlation is generally revealed between the gene
expression signatures of the drug and the disease [8,9]. A schematic diagram representing opposing
gene expression patterns under a disease state and under its drug treatment is shown in Figure 1.
Figure 1. A contrasting gene expression pattern between studies: “disease vs. normal” and “drug
treatment vs. untreated.” Red colored bars indicate over-expression of genes, while green-colored
bars represents under-expressed genes. (A) Differential expression of genes in disease. (B) Opposing
differential expression due to administering a drug (relative to ‘normal’ expression).
Advancements in high-throughput technologies, such as microarrays and RNA-sequencing
methods, allow scientists to measure gene expression patterns under different experimental conditions.
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Scientists routinely deposit gene expression data derived from such experiments into online
repositories, often times making the data freely available [10].
Published studies have shown that the statistical analysis of gene expression data can be utilized
to identify repurposable drugs [8]. However, running these sophisticated correlation statistics on gene
expression datasets requires proficiency in the fields of computer science, bioinformatics and statistics,
along with access to high powered computers. The advent of bioinformatics tools that mine raw gene
expression data from the repository and run sophisticated statistical algorithms plays an important
role in making pre-processed transcriptomics data available to the public.
We have developed a protocol by sequentially connecting disparate existing online bioinformatics
tools, databases and literature search engines to identify repurposable drugs. This protocol, which can
be used by any motivated individual, takes an FDA approved drug as the input and then searches for
diseases that show negatively correlated gene expression in relation to that drug. The efficacy of this
protocol was assessed by comparing the protocol prediction with the results of two recently-published
articles of repurposed drugs: zidovudine [6] and imipramine [7].
2. Methods
2.1. BaseSpace Correlation Engine
The BaseSpace Correlation Engine, formerly NextBio, is a searchable online database maintained
and delivered by Illumina Inc., San Diego, CA, USA (https://www.nextbio.com/) [11]. This database
collects raw experimental data from high-throughput gene expression experiments submitted to global
repositories, such as the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and
Array Express (https://www.ebi.ac.uk/arrayexpress/).
The BaseSpace Correlation Engine utilizes proprietary statistical algorithms to convert raw
experimental data into a list of genes that are differentially expressed in certain conditions along
with their corresponding fold change and p-value calculations. The fold change value indicates
how a given gene is differentially expressed in a test condition compared to the control condition of
an experiment. Examples are experiments with drug treatment vs. non-treatment or disease state vs.
normal state. Rank-based enrichment statistics are then used to compute the pairwise correlation scores
between all gene expression signatures present in the database. The most correlated gene expression
study present for each query was assigned a numerical score of 100, and scores for the rest of the
results were normalized to the top-ranked study. This resource enables users to find gene expression
experiments with given drug-treated versus untreated conditions. Hence, diseases showing strong
negative correlation with a given drug can be identified to predict potentially repurposable drugs.
2.2. PubMed
An online database (https://www.ncbi.nlm.nih.gov/pubmed) is comprised of over 26 million
citations published in 2600 life sciences journals. Many of these citations provide links to the abstract
and full text of the article. This database is freely accessible and maintained by the National Library of
Medicine, a division of the U.S. National Institute of Health.
2.3. In Silico Protocol to Identify Repurposed Drugs
A protocol encompassing the systematic search of the online databases mentioned above enables
users to quickly and efficiently identify potential target diseases for a drug (Figure 2). The steps are
as follows:
a. Identify gene expression studies associated with the drug:
Enter a drug name in the search box of the BaseSpace Correlation Engine and then click on the
icon named “Curated Studies” displayed at the top of the web page. Once the search result is returned,
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click on the “Filter By” option and select “Data Types” available at the top of the page and select
“RNA Expression.”
Browse the search results returned that will display numerous independent gene expression
studies. Identify the studies that compare the gene expressed data for drug treatment vs. control
(untreated). Select the appropriate study by clicking on the hyperlink of that study. Each study may
have multiple experiments measured under different conditions such as a different dosage of the
drug or different treatment time points. Clicking on the study will bring up a page with a detailed
description of the study, as well as links to the gene expression data associated with each experiment.
When the experiment was selected by clicking the hyperlinked title and a table consisting of the
differential gene expression, data will appear on the screen.
b. Search for diseases with negative correlations:
Select the icon “Disease Atlas” available at the top of the page. A web page displaying a table of
various disease names with their corresponding correlation scores will appear. Sort through the table
by selecting “Rank” from the drop-down menu available under the “View By” option displayed at the
top left corner of the page. Re-sort the results by selecting the “−ve Correlation” option present in the
drop-down menu under the “Correlation with Query” column heading at the top of the right-most
column. Finally, select the diseases that have the largest number of studies. The queried drug would
have the potential to treat the selected diseases.
c. Search literature database to validate disease predictions:
Go to PubMed, and enter “the drug name AND the predicted disease name” in the search box
and look for citations.
Figure 2. A three-step online protocol for repurposed drug prediction.
3. Results
This protocol was applied to two previously published repurposed drugs, and the protocol
predictions were compared with the reported findings.
3.1. Case Study 1: Zidovudine
Through experiments performed in mouse models, Fowler et al. reported that the drug
zidovudine, a Nucleoside Reverse Transcriptase Inhibitor (NRTI) usually used to treat HIV patients,
showed strong potential to be used against the untreatable dry form of Age-related Macular
Degeneration (AMD) [6].
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3.1.1. Study Selection from the BaseSpace Correlation Engine
A search for curated studies using the query zidovudine in the BaseSpace Correlation Engine
retrieved 10 RNA-expression studies: six studies based on rat experiments and four from experiments
done on human data. A study titled “Drug Matrix In Vitro Toxicogenomic Study—Rat Hepatocytes
[Affymetrix]” [12,13] was selected for further analysis. Although drug-treatment studies performed
on normal human cell lines would be preferred for repurposed disease prediction, for this query, all
human studies were only carried out for cancer cell lines or virus-infected cells. Hence, they were not
suitable for study selection. On the other hand, the studies based on rat experiments were performed
under normal conditions. Since the liver is a principal site of drug metabolism, a study measuring the
gene expression patterns of rat hepatocyte cells was selected.
In this study, rat hepatocyte cells isolated from male Sprague-Dawley rats were co-cultured
in vitro with varying doses of the drug during different time points. Microarray experiments were
then performed on an Affymetrix platform to measure and compare the gene expression patterns
of treatment versus control conditions. Typically, a gene expression study is comprised of multiple
experiments. Among the three experiments listed under this study, the experiment titled “Primary
rat hepatocytes + ZIDOVUDINE at 14,800 µM in DMSO 1D_vs_vehicle” covered the largest number
of genes (8000). Therefore, the differentially-expressed gene (DEG) profile of the said experiment
was used as a query to seek out Negatively-Correlated (NC) diseases for zidovudine. Figure 3
shows a screenshot taken from the BaseSpace Correlation Engine result page displaying the top ten
differentially-expressed genes.
Figure 3. A screenshot taken from the BaseSpace Correlation Engine-generated result page displaying
the top ten differentially-expressed genes of the selected query study: zidovudine treatment on rat
hepatocyte cells vs. untreated cells.
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3.1.2. Negatively-Correlated Diseases
The BaseSpace Correlation Engine ranks the negatively-correlated diseases based on its assigned
correlation score. The most correlated gene expression study, with the lowest p-value, present for each
query is assigned a numerical score of 100 and scores for the rest of the results were normalized to
the top-ranked study. However, for this protocol, the ranking was manually changed to reflect the
number of supporting, independent studies. This step was taken to bolster the prediction efficiency
with the notion that if more independent experiments found a negative correlation between the drug
and the disease, then its ranking should be stronger (while still maintaining an acceptable score of at
least 50/100 to keep correlation as a factor). Table 1 shows the top 10 negatively-correlated diseases for
HIV-drug zidovudine ordered by the number of supported gene expression studies.
Among the diseases listed in the table, human immunodeficiency virus infection, the intended
target of zidovudine, is present (No. 5). The gene expression profiles derived from twenty-one studies
revealed a strong statistically-significant negative correlation (score: 62) with the expression pattern
of zidovudine.
Table 1. Top 10 negatively-correlated diseases for HIV: drug zidovudine ordered by the number of












1. Lupus Erythematosus 45 65 Yes [14]
2. Cardiovascular Diseases 26 54 No
3. Lymphoid Leukemia 25 58 Yes [15]
4. Neuropathy 24 65 No
5. Human Immunodeficiency
Virus Infection 21 62 Yes [6]
6. Mycobacteriosis 19 67 No
7. Rheumatoid Arthritis 19 58 No
8. Myopathy 17 64 No
9. Retinal Disorder 17 60 Yes [6]
10. Dermatitis 17 50 No
Figure 4 displays a comparison of gene expressions between the query experiment and the
experiment “CD8+ T cells from chronic HIV infection patients _vs_ negative control” listed under
the study “HIV-infected individuals with various clinical stages of HIV infection” performed by
Hyrcza et al. [16]. Since the protocol correctly predicted that zidovudine could treat HIV, its intended
target, this finding serves as a valuable result to prove the efficacy of this protocol.
For Age-related Macular Degeneration (AMD), the published finding [6] that we sought falls
under the broader term “retinal disorder,” which is present in the list of the NC diseases (No. 9).
The DEG profile of the experiment “Macular retina—GA Age-related macular degeneration vs. normal
tissue” as part of the study “Age-related macular degeneration subtype expression analysis” revealed
a strong negative correlation with the gene expression profile of zidovudine [17].
Apart from HIV, the intended target of zidovudine, all other NC diseases are novel findings, as
they are not listed as a therapeutic target of zidovudine in well-known drug information resources,
such as DrugBank [18] and the National Library of Medicine Drug Information Portal [19]. While the
potential of this drug to treat AMD has been recently published, a literature search was conducted
to collect evidence on whether the other NC diseases found have been connected to zidovudine.
A literature search found Marcais et al. reported that the treatment of zidovudine is highly effective in
the treatment of a leukemic subtype of adult t-cell lymphoma [15]. Furthermore, Beck-Engeser et al.
published a paper on the efficacy of zidovudine treatment against lupus erythematosus [14]. However,
no literature evidence was found for cardiovascular disease, neuropathy, mycobacteriosis, rheumatoid
arthritis, myopathy or dermatitis.
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Figure 4. A screenshot was taken from the BaseSpace Correlation Engine showing
a statistically-significant negative correlation among differentially-expressed genes from two
experiments: “CD8+ T cells from acute HIV-infected patients’ vs negative control” and the query
study “Zidovudine treatment on rat hepatocyte vs. negative control (vehicle treated cells).”
3.2. Case Study 2: Imipramine
In 2013, Jahchan and colleagues reported that the Tricyclic Antidepressant (TCA) imipramine
could be efficiently repurposed to treat small-cell lung carcinoma [7]. In a protocol of their own,
this study sought small molecules with the ability to treat the apparently recalcitrant form of lung
cancer first by analyzing the disease-derived transcriptomic data and then by running experiments in
an animal model. One of the small molecules identified was imipramine.
3.2.1. Study/Experiment Selection from BaseSpace Correlation Engine
A search for Imipramine (performed on 20 June 2016) in the BaseSpace Correlation Engine
results in eight studies. The DEG profile derived from the experiment titled “Hepatocytes of female
donors treated 24hr with 15uM imipramine _vs_ 0uM” done in human as a part of the study
“Genomics Assisted Toxicity Evaluation system study—Human Hepatocytes” was selected for target
disease prediction through this protocol [20].
3.2.2. Negatively Correlated Diseases:
A list of NC diseases based on the DEG profile expressed by the selected query experiment is
presented in Table 2. The list shows a preponderance of cancer subtypes. Note that small-cell lung
carcinoma, the reported therapeutic target for imipramine, is present in the NC disease list under
lung cancer (No. 3). Hence, the findings reported by Jahchan et al. [7] were successfully replicated by
this in silico protocol. A literature search on imipramine retrieved previously published articles that
studied the treatment of imipramine on two of the predicted target diseases: breast cancer [21] and
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brain cancer [22]. However, no supporting evidence from the literature was found for the treatment
of liver cancer, kidney cancer, inflammatory bowel disease or Severe Acute Respiratory Syndrome
(SARS) using imipramine. The prediction of SARS is notable because it revealed the highest correlation
score of 100. However, the lack of reported evidence on the repositioning of imipramine against SARS
further emphasizes the novelty of this prediction.
Table 2. Top 10 negatively-correlated diseases ordered by the number of supported gene expression














Breast Cancer 57 65 Yes [21]
Allergic Disorder 50 65 Yes [23]
Lung Cancer 49 65 Yes [7]
Liver Cancer 47 65 No
Brain Cancer 44 66 Yes [22]
Inflammatory Bowel Disease 32 66 No
Cardiomyopathy 28 68 No
Kidney Cancer 26 68 No
Nerve Injury 23 79 Yes [24]
Severe Acute Respiratory Syndrome 14 100 No
4. Conclusions
We have been able to verify the findings of previously reported results for two drugs: HIV-drug
zidovudine and tricyclic antidepressant drug imipramine. Through this protocol, HIV-treating
drug zidovudine was found to have the potential to be repurposed as a drug for dry age-related
macular degeneration [17] along with several other diseases, including lupus erythematosus,
cardiovascular disease, lymphoid leukemia, neuropathy, mycobacteriosis, rheumatoid arthritis and
dermatitis. Among these, four of the findings were supported by evidence from published literature.
Imipramine could have the potential to treat small-cell lung carcinoma [7]. Furthermore, we found that
imipramine has the potential to treat several other diseases, including breast cancer, allergic disorder,
liver cancer, brain cancer, inflammatory bowel disorder, cardiomyopathy, kidney cancer, nerve injury
and Severe Acute Respiratory Syndrome (SARS). Five of the results found have been supported with
published literature.
5. Limitations
This online repurposed drug prediction protocol depends on the availability of access to the
BaseSpace Correlation Engine and its analysis of transcriptomics data. If the data for a given drug are
not available, the protocol cannot be applied to that drug.
Furthermore, the DEG data gathered from experiments that compare the effect of the drug
treatment on a normal (non-diseased) human cell line or tissue to the untreated or vehicle treated
condition are considered to be ideal datasets for this method. However, for many drugs, such datasets
are not available. Instead, the available DEG data come from experiments on human cancer cell lines
or from experiments performed on animal models, such as mouse and rat. The protocol utilizing the
non-ideal dataset may infer erroneous predictions and requiring additional analysis.
The BaseSpace Correlation Engine was freely available to the research community, and the authors
received free access upon request to the vendor. However, currently, the tool requires paid subscription
with a fifteen-day free trial option.
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6. Discussion
The case studies mentioned here substantiate the target disease prediction accuracy for a drug by
this protocol. The finding that imipramine could be repurposed to treat small-cell lung cancer was
an expected finding as transcriptomics data analysis was employed by both the literature described
methods, as well as by this in silico protocol. However, the correct prediction that the dry form of
AMD may be a target disease is noteworthy because the underlying discovery methods were different.
The literature [6] used a small molecule screening technique, while this in silico protocol applied
transcriptomics data analysis. This finding further adds credence to the strategy adopted by this
protocol to predict diseases a given drug can be repurposed toward.
The prediction that imipramine could be repurposed against SARS is a significant observation.
SARS is a deadly viral disease, and during the period of 2002 to 2003, an outbreak caused over
8000 cases with 772 deaths reported in 37 countries [25]. As of today, there is no treatment or vaccines
available for SARS. This makes the predictions made by this protocol particularly advantageous for
such deadly diseases by giving patients a possible treatment [26]. Because this is a novel finding,
further clinical investigation measuring the potency of imipramine against SARS in human would
be needed.
The in silico protocol described in this study leverages pre-processed transcriptomics data
available through the BaseSpace Correlation Engine database. This method is straight forward,
simple to use and does not require advanced computer skills. Hence, it may be beneficial to users
including researchers, clinicians, patients and even high school students who can apply this method
and identify the existing drugs that can be repurposed to serve as new therapeutic targets for various
diseases in the future. We hope this protocol could be utilized as a crowdsourcing tool for drug
discovery research.
7. Citizen Science
This work describes a protocol by which existing tools and databases can be utilized to draw novel
results through human computation. We hope that in the event of epidemics, such as viral infections
or transmittable diseases, the global scientific community, especially high school and undergraduate
students, could employ this protocol to shortlist drugs that may be useful. We created an online
form where the outcomes of such citizen science could be collected. The online form is available at
http://severus.dbmi.pitt.edu/SSDR. Upon receiving submissions with this form, we will post them
for world-wide users to view them on a separate page under the same website.
Author Contributions: AC is a high school student (12th grade) and carried out this work and wrote the
manuscript with supervision from MKG. The manuscript has been read and approved by both authors.
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